Vendor review
Uther reviews
Uther reviews from 100 independent lab tests (Retatrutide, Tirzepatide and BPC-157): grade A, purity and fill accuracy. Is Uther legit? See what its vials showed.
What the lab tests show
100 tests on record, newest first. Scores are purity divided by ten.
| Date | Product | Purity | Quantity | Identity | Certificate |
|---|---|---|---|---|---|
| Jul 20, 2026 | GHK-Cu | 99.9 % | 52.1 mg of 50 mg (4 %) | Pass | View |
| Jul 20, 2026 | Tirzepatide | 99.9 % | 29 mg of 30 mg (-3 %) | Pass | View |
| Jul 1, 2026 | Tesamorelin | 99.9 % | 11.8 mg of 10 mg (18 %) | Pass | View |
| Jun 8, 2026 | Tesamorelin | 99.8 % | 26.6 mg of 20 mg (33 %) | Pass | View |
| Jun 8, 2026 | Retatrutide | 99.8 % | 38.9 mg of 30 mg (30 %) | Pass | View |
| Jun 8, 2026 | Ipamorelin | 99.9 % | 11.5 mg of 10 mg (15 %) | Pass | View |
| Jun 6, 2026 | Tesamorelin | 20 mg | View | ||
| Jun 6, 2026 | Ipamorelin | 10 mg | View | ||
| Jun 6, 2026 | Retatrutide | 30 mg | View | ||
| Jun 1, 2026 | Cagrilintide | 99.8 % | 5.28 mg of 5 mg (6 %) | Pass | View |
| May 8, 2026 | Ipamorelin | 97.7 % | 11.3 mg of 10 mg (13 %) | Pass | View |
| Apr 28, 2026 | GHK-Cu | 99.9 % | 117.9 mg of 100 mg (18 %) | Pass | View |
| Apr 28, 2026 | Tirzepatide | 60 mg | Fail | View | |
| Apr 28, 2026 | Retatrutide | 99.9 % | 30.4 mg of 30 mg (1 %) | Pass | View |
| Apr 28, 2026 | Retatrutide | 99.8 % | 22.8 mg of 20 mg (14 %) | Pass | View |
| Apr 28, 2026 | PT-141 | 99.9 % | 10.3 mg of 10 mg (3 %) | Pass | View |
| Apr 23, 2026 | Survodutide | 99.9 % | 10.8 mg of 10 mg (8 %) | Pass | View |
| Mar 25, 2026 | Tesamorelin | 99.7 % | 20.6 mg of 20 mg (3 %) | Pass | View |
| Mar 20, 2026 | Tesamorelin | 99.8 % | 23.7 mg of 20 mg (19 %) | Pass | View |
| Mar 13, 2026 | Cagrilintide | 99.2 % | 3.7 mg of 5 mg (-26 %) | Pass | View |
| Mar 7, 2026 | TB-500 | 99.8 % | 9.7 mg of 10 mg (-3 %) | Pass | View |
| Mar 7, 2026 | CJC-1295 | 99.9 % | 9.6 mg of 10 mg (-4 %) | Pass | View |
| Mar 6, 2026 | Tirzepatide | 99.9 % | 52.1 mg of 60 mg (-13 %) | Pass | View |
| Mar 6, 2026 | Tesamorelin | 10 mg | Fail | View | |
| Mar 6, 2026 | Ipamorelin | 99.9 % | 9.95 mg of 10 mg (-1 %) | Pass | View |
| Mar 6, 2026 | PT-141 | 99.9 % | 8.44 mg of 10 mg (-16 %) | Pass | View |
| Mar 6, 2026 | CJC-1295 | 99.9 % | 10.5 mg of 10 mg (5 %) | Pass | View |
| Mar 6, 2026 | BPC-157 | 99.9 % | 10.3 mg of 10 mg (3 %) | Pass | View |
| Mar 4, 2026 | GHK-Cu | 99.7 % | 27.7 mg of 50 mg (-45 %) | Pass | View |
| Mar 4, 2026 | Retatrutide | 99.2 % | 5.2 mg of 5 mg (4 %) | Pass | View |
| Mar 4, 2026 | Retatrutide | 99.6 % | 10 mg of 10 mg (0 %) | Pass | View |
| Mar 2, 2026 | TB-500 | 99.5 % | 4.81 mg of 2 mg (141 %) | Pass | View |
| Mar 2, 2026 | BPC-157 | 99.9 % | 4.22 mg of 5 mg (-16 %) | Pass | View |
| Mar 1, 2026 | Retatrutide | 99.8 % | 33.1 mg of 30 mg (10 %) | Pass | View |
| Feb 26, 2026 | CJC-1295 | 5 mg | Fail | View | |
| Feb 20, 2026 | BPC-157 | 99.9 % | 19.2 mg of 20 mg (-4 %) | Pass | View |
| Feb 18, 2026 | Retatrutide | 99.9 % | 17 mg of 30 mg (-43 %) | Pass | View |
| Feb 10, 2026 | Tesamorelin | 99.8 % | 25.8 mg of 20 mg (29 %) | Pass | View |
| Feb 10, 2026 | Ipamorelin | 99.9 % | 10.4 mg of 10 mg (4 %) | Pass | View |
| Feb 10, 2026 | TB-500 | 99.8 % | 11.9 mg of 10 mg (19 %) | Pass | View |
| Feb 10, 2026 | Retatrutide | 99.7 % | 11.1 mg of 10 mg (11 %) | Pass | View |
| Jan 26, 2026 | GHK-Cu | 99.9 % | 121 mg of 100 mg (21 %) | Pass | View |
| Jan 26, 2026 | BPC-157 | 99.9 % | 11.2 mg of 10 mg (12 %) | Pass | View |
| Jan 6, 2026 | Tirzepatide | 99.12 % | 12.4 mg of 15 mg (-17 %) | Pass | View |
| Dec 30, 2025 | Tirzepatide | 99.95 % | 39.9 mg of 40 mg (0 %) | Pass | View |
| Dec 29, 2025 | Tirzepatide | 99.95 % | 97.1 mg of 100 mg (-3 %) | Pass | View |
| Dec 29, 2025 | Ipamorelin | 99.68 % | 5.14 mg of 5 mg (3 %) | Pass | View |
| Dec 29, 2025 | Semaglutide | 99.95 % | 5.25 mg of 5 mg (5 %) | Pass | View |
| Dec 18, 2025 | Tirzepatide | 99.7 % | 17.8 mg of 15 mg (19 %) | Pass | View |
| Nov 25, 2025 | BPC-157 | 99.95 % | 24.6 mg of 20 mg (23 %) | Pass | View |
| Nov 25, 2025 | CJC-1295 | 5 mg | Fail | View | |
| Nov 17, 2025 | BPC-157 | 99.38 % | 11 mg of 10 mg (10 %) | Pass | View |
| Nov 6, 2025 | GHK-Cu | 99.95 % | 123 mg of 100 mg (23 %) | Pass | View |
| Nov 6, 2025 | Retatrutide | 99.95 % | 35.4 mg of 40 mg (-12 %) | Pass | View |
| Nov 6, 2025 | Retatrutide | 99.85 % | 9.98 mg of 10 mg (0 %) | Pass | View |
| Nov 4, 2025 | Tirzepatide | 99.95 % | 10.7 mg of 10 mg (7 %) | Pass | View |
| Nov 4, 2025 | Ipamorelin | 98.65 % | 11.5 mg of 10 mg (15 %) | Pass | View |
| Oct 30, 2025 | Tirzepatide | 99.8 % | 64.37 mg of 60 mg (7 %) | Pass | View |
| Oct 23, 2025 | Survodutide | 99.22 % | 11.8 mg of 10 mg (18 %) | Pass | View |
| Oct 17, 2025 | Tirzepatide | 99.95 % | 29.2 mg of 30 mg (-3 %) | Pass | View |
What Uther sells
No current listings on record.
About Uther
https://a2d4053c31322f67.en.made-in-china.com/